CAPR Capricor Therapeutics, Inc.

NASDAQ
$6.65

Capricor Therapeutics, Inc. (CAPR) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.2% since its last earnings release on August 13, 2026.

Capricor Therapeutics Missed Consensus Estimates
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.55)
Rev est $700K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Capricor Therapeutics, Inc.

Capricor Therapeutics Inc is a development stage biopharmaceutical company developing products for the treatment of cardiovascular diseases with a focus on heart failure.

Sector

Healthcare

Industry

Biotechnology